Dianthus Therapeutics (DNTH) News Today $18.27 -0.02 (-0.11%) Closing price 03/26/2025 04:00 PM EasternExtended Trading$18.65 +0.38 (+2.09%) As of 03/26/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.8% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8% - Here's What HappenedMarch 18, 2025 | marketbeat.comDianthus Therapeutics (DNTH) Expected to Announce Quarterly Earnings on ThursdayMarch 18, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for DNTH FY2025 EarningsMarch 18, 2025 | americanbankingnews.comFY2025 EPS Estimates for DNTH Raised by Cantor FitzgeraldDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for Dianthus Therapeutics in a research note issued to investors on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the cMarch 17, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for DNTH EarningsDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now forecMarch 17, 2025 | marketbeat.comWhat is Lifesci Capital's Estimate for DNTH FY2025 Earnings?Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at Lifesci Capital increased their FY2025 earnings estimates for shares of Dianthus Therapeutics in a research note issued to investors on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now expects that the coMarch 15, 2025 | marketbeat.comWedbush Analysts Decrease Earnings Estimates for DNTHDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at Wedbush decreased their Q1 2025 EPS estimates for shares of Dianthus Therapeutics in a research note issued on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.74) per sharMarch 15, 2025 | marketbeat.comStifel maintains Buy rating on Dianthus Therapeutics stockMarch 14, 2025 | uk.investing.comDianthus Therapeutics shares fall as Q4 results miss expectationsMarch 14, 2025 | investing.comWe're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn RateMarch 13, 2025 | finance.yahoo.comDianthus Therapeutics Full Year 2024 Earnings: Beats ExpectationsMarch 13, 2025 | finance.yahoo.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - What's Next?March 13, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH)Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday.March 13, 2025 | marketbeat.comDianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at GuggenheimGuggenheim reaffirmed a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday.March 13, 2025 | marketbeat.comDianthus Therapeutics' (DNTH) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday.March 13, 2025 | marketbeat.comDianthus Therapeutics (DNTH) to Release Quarterly Earnings on ThursdayDianthus Therapeutics (NASDAQ:DNTH) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comDianthus Therapeutics Reports 2024 Financial Results and Clinical ProgressMarch 13, 2025 | tipranks.comDianthus Therapeutics (NASDAQ:DNTH) Announces Earnings Results, Beats Estimates By $0.04 EPSDianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.March 12, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - Time to Sell?Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - What's Next?March 12, 2025 | marketbeat.comDianthus reports Q4 EPS (81c), consensus (76c)March 12, 2025 | markets.businessinsider.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by BrokeragesDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine analysts that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have issued a stMarch 12, 2025 | marketbeat.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial ResultsMarch 11, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Trading 8.2% Higher - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Trading 8.2% Higher - What's Next?March 6, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month Low - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month Low - Should You Sell?March 5, 2025 | marketbeat.comDianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of DirectorsMarch 5, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.3% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.3% - Time to Sell?March 3, 2025 | marketbeat.comDianthus Therapeutics to Participate in Two Upcoming Investor ConferencesFebruary 26, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.6% - Here's What HappenedDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.6% - What's Next?February 24, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by AnalystsShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two hFebruary 15, 2025 | marketbeat.comStifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)February 10, 2025 | markets.businessinsider.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Trading 8% Higher - Here's What HappenedFebruary 5, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 6.0% in JanuaryDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 6,000,000 shares, an increase of 6.0% from the December 31st total of 5,660,000 shares. Based on an average trading volume of 250,800 shares, the days-to-cover ratio is currently 23.9 days. Approximately 31.2% of the shares of the company are sold short.February 4, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Increase in Short InterestDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 6,000,000 shares, a growth of 6.0% from the December 31st total of 5,660,000 shares. Based on an average trading volume of 250,800 shares, the days-to-cover ratio is presently 23.9 days. Currently, 31.2% of the shares of the stock are sold short.February 3, 2025 | marketbeat.comDianthus Therapeutics to Webcast Presentations at Two Investor ConferencesJanuary 30, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6% - Here's What HappenedJanuary 23, 2025 | marketbeat.comCantor Fitzgerald Forecasts DNTH FY2025 EarningsDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Dianthus Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts thatJanuary 22, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by AnalystsDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus rating of "Buy" from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy ratingJanuary 21, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short InterestDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 6,000,000 shares, an increase of 6.0% from the December 15th total of 5,660,000 shares. Based on an average trading volume of 250,800 shares, the days-to-cover ratio is currently 23.9 days. Approximately 31.2% of the company's stock are short sold.January 19, 2025 | marketbeat.comBarclays PLC Acquires 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 390.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,684 shares of the company's stock after acquiring an additional 33,185January 14, 2025 | marketbeat.comDianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8% - Should You Sell?Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 6.8% - Here's WhyJanuary 7, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.8% - Should You Buy?Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.8% Higher - Here's WhyJanuary 6, 2025 | marketbeat.comJane Street Group LLC Takes $556,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Jane Street Group LLC purchased a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 20,316 shares of the company's stock, valued at approximately $556,000. Jane Street Group LLC owneJanuary 6, 2025 | marketbeat.comBarclays PLC Boosts Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 390.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 41,684 shares of the company's stock after purchasing an additional 33,185 shares during the quarter. BarclaysDecember 30, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by BrokeragesDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been given a consensus rating of "Buy" by the ten brokerages that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. TDecember 27, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 2.5% - What's Next?Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 2.5% - Should You Sell?December 26, 2024 | marketbeat.comState Street Corp Increases Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)State Street Corp grew its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 101.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 821,131 shares of the company's stock after purchasing aDecember 23, 2024 | marketbeat.comTD Cowen Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy RecommendationDecember 21, 2024 | msn.comForecasting The Future: 5 Analyst Projections For Dianthus TherapeuticsDecember 20, 2024 | benzinga.comDianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at TD CowenTD Cowen began coverage on shares of Dianthus Therapeutics in a research note on Friday. They set a "buy" rating for the company.December 20, 2024 | marketbeat.com Remove Ads Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address DNTH Media Mentions By Week DNTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNTH News Sentiment▼0.710.85▲Average Medical News Sentiment DNTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNTH Articles This Week▼13▲DNTH Articles Average Week Remove Ads Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bausch Health Companies News NewAmsterdam Pharma News Twist Bioscience News Edgewise Therapeutics News ImmunityBio News MoonLake Immunotherapeutics News Beam Therapeutics News Vericel News Centessa Pharmaceuticals News Denali Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNTH) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DNTH Stock Free DNTH Stock Alerts